NASDAQ:GDRX GoodRx (GDRX) Stock Price, News & Analysis $6.12 -0.26 (-4.08%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About GoodRx Stock (NASDAQ:GDRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GoodRx alerts:Sign Up Key Stats Today's Range$6.12▼$6.3950-Day Range$6.21▼$8.5952-Week Range$4.14▼$9.26Volume599,631 shsAverage Volume1.37 million shsMarket Capitalization$2.32 billionP/E RatioN/ADividend YieldN/APrice Target$9.36Consensus RatingModerate Buy Company OverviewGoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.Read More… 24/7 Automated Profits in Crypto (Ad)What if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast world of passive crypto income, where you set up a dependable income stream that works for you, whether you're at your computer or living your life.>> Secure Your Spot On The Groundbreaking Workshop Here GoodRx Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks66th Percentile Overall ScoreGDRX MarketRank™: GoodRx scored higher than 66% of companies evaluated by MarketBeat, and ranked 406th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingGoodRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 9 buy ratings, 4 hold ratings, and 1 sell rating.Amount of Analyst CoverageGoodRx has only been the subject of 4 research reports in the past 90 days.Read more about GoodRx's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth57.14% Earnings GrowthEarnings for GoodRx are expected to grow by 57.14% in the coming year, from $0.14 to $0.22 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GoodRx is -48.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GoodRx is -48.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioGoodRx has a PEG Ratio of 4.17. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGoodRx has a P/B Ratio of 3.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about GoodRx's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.04% of the float of GoodRx has been sold short.Short Interest Ratio / Days to CoverGoodRx has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in GoodRx has recently decreased by 0.78%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGoodRx does not currently pay a dividend.Dividend GrowthGoodRx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.04% of the float of GoodRx has been sold short.Short Interest Ratio / Days to CoverGoodRx has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in GoodRx has recently decreased by 0.78%, indicating that investor sentiment is improving. News and Social Media2.4 / 5News Sentiment0.32 News SentimentGoodRx has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for GoodRx this week, compared to 7 articles on an average week.Search Interest5 people have searched for GDRX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added GoodRx to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, GoodRx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $83,921.00 in company stock.Percentage Held by InsidersOnly 4.17% of the stock of GoodRx is held by insiders.Percentage Held by Institutions63.77% of the stock of GoodRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GoodRx's insider trading history. Receive GDRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GoodRx and its competitors with MarketBeat's FREE daily newsletter. Email Address GDRX Stock News HeadlinesKuehn Law Encourages Investors of GoodRx Holdings, Inc. to Contact Law FirmOctober 31 at 3:17 PM | globenewswire.comGoodRx Unveils New E-commerce Platform, Launches with Opill®October 31 at 10:26 AM | finance.yahoo.comMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.October 31, 2024 | Paradigm Press (Ad)Cautious Outlook and Sell Rating for GoodRx Holdings Amid Limited Market Potential and Overvaluation ConcernsOctober 31 at 5:25 AM | markets.businessinsider.comGoodRx stock moves on exclusive 30-day offer of weight management drug QsymiaOctober 30 at 2:26 AM | uk.finance.yahoo.comGoodRx announces exclusive cash price for QsymiaOctober 29 at 9:26 PM | markets.businessinsider.comGoodRx Holdings Strengthens Board with New AppointmentOctober 29 at 11:23 AM | markets.businessinsider.comGoodRx Announces Exclusive Low Cash Price for QSYMIA®, the Leading Branded Once-Daily Oral Weight Management Medication for AdultsOctober 29 at 11:23 AM | finance.yahoo.comSee More Headlines GDRX Stock Analysis - Frequently Asked Questions How have GDRX shares performed this year? GoodRx's stock was trading at $6.70 at the start of the year. Since then, GDRX stock has decreased by 6.7% and is now trading at $6.25. View the best growth stocks for 2024 here. How were GoodRx's earnings last quarter? GoodRx Holdings, Inc. (NASDAQ:GDRX) announced its quarterly earnings data on Thursday, August, 8th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by $0.01. The business's revenue for the quarter was up 5.7% on a year-over-year basis. When did GoodRx IPO? GoodRx (GDRX) raised $900 million in an IPO on Wednesday, September 23rd 2020. The company issued 34,600,000 shares at a price of $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays acted as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers. Who are GoodRx's major shareholders? Top institutional shareholders of GoodRx include Raymond James & Associates (0.11%), Assenagon Asset Management S.A. (0.10%), Vontobel Holding Ltd. (0.02%) and Kesler Norman & Wride LLC (0.02%). Insiders that own company stock include Scott Wagner, Equity Vii LP Spectrum, Idea Men, Llc, Abdiel Capital Management, Llc, Trevor Bezdek, Babak Azad, Karsten Voermann and Andrew Slutsky. View institutional ownership trends. How do I buy shares of GoodRx? Shares of GDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of GoodRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that GoodRx investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings8/08/2024Today10/31/2024Next Earnings (Confirmed)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Data processing & preparation Sub-IndustryBusiness Services Current SymbolNASDAQ:GDRX CUSIPN/A CIK1809519 Webwww.goodrx.com Phone855-268-2822FaxN/AEmployees950Year FoundedN/APrice Target and Rating Average Stock Price Target$9.36 High Stock Price Target$16.00 Low Stock Price Target$4.50 Potential Upside/Downside+49.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($0.13) Trailing P/E RatioN/A Forward P/E Ratio44.71 P/E Growth4.17Net Income$-8,870,000.00 Net Margins-7.57% Pretax Margin-7.65% Return on Equity3.63% Return on Assets1.72% Debt Debt-to-Equity Ratio0.96 Current Ratio7.32 Quick Ratio7.32 Sales & Book Value Annual Sales$775.09 million Price / Sales3.06 Cash Flow$0.39 per share Price / Cash Flow15.99 Book Value$1.93 per share Price / Book3.24Miscellaneous Outstanding Shares379,453,000Free Float363,630,000Market Cap$2.38 billion OptionableOptionable Beta1.37 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:GDRX) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GoodRx Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GoodRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.